ENTRESTO® (sacubitril/valsartan)

In most patients with HF, help HEART FAILURE MEET HEART SUCCESS¹

Start ENTRESTO^® to help reduce the risk of CV death and HF hospitalization

Results for HFrEF Results for HFpEF with LVEF ≤60%*

^†In the 2022 HF Guideline, ENTRESTO is recommended as a first-line treatment and to replace well-tolerated ACEi/ARB in patients with NYHA Class II–III HFrEF (Class 1 recommendation). ENTRESTO was also included as a treatment option for HFmrEF (LVEF 41%–49%) and select patients with HFpEF (LVEF ≥50%), particularly for patients with LVEF on the lower end of the spectrum (Class 2b recommendation).

*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.¹

Start ENTRESTO, the preferred RASi^† in HFrEF instead of ARB²

See the single dosing regimen for most patients with heart failure^1,3-5

Discover support and resources to help your patients start on Entresto

Important Safety Information

Indication

Definitions & References

Start ENTRESTO, the preferred RASi† in HFrEF instead of ARB2

See the single dosing regimen for most patients with heart failure1,3-5

Discover support and resources to help your patients start on Entresto

Definitions & References

Start ENTRESTO, the preferred RASi^† in HFrEF instead of ARB²

See the single dosing regimen for most patients with heart failure^1,3-5